http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : 김삼현(Sam Hyu (검색결과 2 건)
- 무료
- 기관 내 무료
- 유료
-
박성식,김삼현,서필원,최창휴,이상훈,이혁수,황승옥,안혁,Park, Seong-Sik,Kim, Sam-hyun,Seo, Pil-won,Choi, Chang-hyu,Lee, Sang-hoon,Lee, Hyuk-soo,Hwang, Seung-ok,Ahn, Hyuk 대한흉부심장혈관외과학회 1999 Journal of Chest Surgery (J Chest Surg) Vol.32 No.12
Background : Ventricular assist devices(VADs) are being used for patients in postcvardiotomy cardiogenic shock status bridge to cardiac transplant settings and in post-myocardial infarction cardiogenic shock. The VAD which was developed at the Deparment of medical engineering in Dankook University College of Medicine was a pneumatically driven device and can maintain pulsatile flow. The goal of this study is to develop animal experimental models using the VAD and to clarify the reliability and hemodynamic property adequacy of end organ perfusion durability and severity of thrombotic-hemolytic tendency of the device. Material and Method : The pneumatic VAD was applied to 8 adult female lambs, We examined some hemodynamic parameters such as arterial blood pressure pulmonary capillary wedge pressure(pcwp) pulmonary artery pressure(PAP) left atrial pressure hour urine output cardiac index VAD flow EKG to determine the reliability of the VAD and hemodynamic compatibility of the experimental animals within 24 hours of experiment. We also observed the end organ perfusion durability of the VAD and thrombotic-hemolytic property of the VAD after 24 hours of VAD insertion. Result: We could monitor all hemodynamic parameters including pcwp PAP cardiac index EKG, adn hour urine as true clinical settings. We observed that the reliability of the VAD was excellent and the hemodynamic property of the experimental animal and end organ perfusion were adequate within 24 hours of experiment. In four lambs surviving 24 hours after insertion the reliability of the VAD and end organ perfusion were excellent and no thrombotic-hemolytic tendency was noted. However after 15 days of experiment the diaphragm of the VAD was torn and it was recommende that the durability of the VAD should be extended. Conclusion : e conclude that the pneumatic VAD developed at Dankook University Biomedical Engineering has good hemodynamic property and low thromboembolic tendency and presents adequate end organ perfusion but we noted that the durability of the device should be expanded further. It will be possible to do more reliable experiment in the future according to the animal experimental method developed in this study especially with the heart failure models.
-
최은경(Euk Kyung Choi),장혜숙(Hyesook Chang),서철원(Cheolwon Suh),이규형(Kyoo Hyung Lee),이정신(Jung Sing Lee),김상희(Sang Hee Kim),최철준(Chul Joon Chio),고윤석(Youn Suck Koh),김우성(Woo Sung Kim),김원동(Won Dong Kim),김삼현(Sam Hyu 대한방사선종양학회 1991 Radiation Oncology Journal Vol.9 No.2
제3기의 진행성 비소세포 폐암에서의 MVP 항암 요법과 다분할 방사선 치료의 효과를 판정하기 위하여 1991년 1월부터 전향성 임의선택 연구(prospective randomized study)를 시작하였다. 본 연구는 제Ⅲ기의 비소세포 폐암중 절제가 불가능한 환자를 대상으로 하여 MVP 항암요법(Mitomycin C 6mg/㎡, Vinblastine 6mg/㎡, Cisplatin 60mg/㎡)을 3회 시행한 후 다분할 방사선치료 (120cGy/fx, BID)를 6500cGy까지 조사하였다. 방사선치료가 끝난 1개월 후 관해정도를 확인하여 추가 항암요법을 시행하는 군과 계속 관찰하는 군으로 임의 분류하였다. 1991년 8월까지 18명의 환자가 등록 되었으며 이중 2명은 2cycle의 항암요법 후 치료를 포기하여 16명의 환자에 대한 분석을 시행하였다. MVP항암요법에 대한 관해율은 62.5%로 50%에서는 부분관해 12.5%에서는 minimal response를 보였다. 항암요법에 부분관해를 보인 3명중 1명에서는 방사선 치료후 완전관해를 보였으며 항암요법으로 병이 진행된 6명의 환자중 4명에서는 방사선 치료후에도 역시 병이 진행되는 것을 알 수 있었다. 모든 환자는 다분할 방사선 치료를 잘 견뎠으나 한 환자가 방사선 치료 한달 후 항암요법과 관련된 부작용으로 사망하였다. 아직 추적관찰 기간이 짧고 대상환자가 많지 않다는 문제점은 있으나 본 연구를 계속 진행함으로써 유의한 결과를 얻을 수 있을 것으로 기대된다. To evaluate the effect of MVP chemontherapy and hyperfractionated radiotherapy in StageⅢ unresectable non small cell lung cancer(NSCLC), authors have conducted a prospective randomized study since January 1991. StageⅢa or Ⅲb unresectable NSCLC patients were treated with hyperfractionated radiotherapy (120cGy/fx, BID) up to 6500 cGy followng 3 cycles of induction MVP(Mitomycin C 6mg/㎡, Vinblastine 6mg/㎡, Cisplatin 60mg/㎡) and randomized for either observation or 3cycles of maintenance MVP chemontherapy. Until August 1991, 18 patients were registered to this study. 4cases were stage Ⅲa and 14 were stage Ⅲb. Among 18 cases 2 were lost after 2 cycles of chemonterapy, and 16 were analyzed for this preliminary report. The response rate of induction chemotherapy was 62.5%; partial response, 50% and minimal response, 12.5%. Residual tumor of the one partial responder was completely disappeared after radiotherapy. Among 6cases sho were progressed during induction chemotherapy, 4 of them were also progressed after radiotherapy. All patients were tolerated BID radiotherapy without definite increase of acute complications, compared with conventional radiotherapy group. But at the time of this report, one patient expired in two month after the completion of the radiotherapy because of treatment related complication. Although the longer follow up is needed, autors are encouraged with higher response rate and acceptable toxicity of this treatment. Authors believe that study is worthshile to continue.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
